Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 10:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 180 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High Grade Glioma: Gliosarcoma Clear all
Completed Phase 1 Interventional

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

NCT01257594
View directory record Official record
Conditions
Brain Cancer
Interventions
erlotinib, Cytoreductive Surgery
Drug · Procedure
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
4
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Internal Radiation Therapy Plus Carmustine Implants in Treating Patients With Recurrent or Refractory Malignant Glioma

NCT00003876
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
polifeprosan 20 with carmustine implant, surgical procedure, iodine I 125
Drug · Procedure · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

O(6)-Benzylguanine in Treating Patients With Malignant Glioma

NCT00002971
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
O6-benzylguanine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available

Panitumumab and Irinotecan for Malignant Gliomas

NCT01017653
View directory record Official record
Conditions
Malignant Glioma of Brain
Interventions
Irinotecan, Panitumumab
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Gliadel Followed by Avastin + Irinotecan for Glioblastoma Multiforme (GBM)

NCT00735436
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Gliadel/Avastin/CPT-11
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab Beyond Progression (BBP)

NCT01740258
View directory record Official record
Conditions
Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
Interventions
Radiation Therapy, Temozolomide, Bevacizumab
Radiation · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 11, 2026, 10:15 PM EDT
Withdrawn Phase 2 Interventional

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

NCT00006263
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, carboplatin, temozolomide
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

NCT02661282
View directory record Official record
Conditions
Cytomegalovirus Positive, Glioblastoma, Gliosarcoma, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Glioblastoma
Interventions
Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, Temozolomide, Therapeutic Conventional Surgery
Biological · Other · Drug + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Gene Therapy in Treating Patients With Recurrent Malignant Gliomas

NCT00004041
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Ad5CMV-p53 gene, conventional surgery
Biological · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

NCT00047281
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
celecoxib, cyclophosphamide, etoposide, thalidomide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma

NCT00498927
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunoenzyme technique
Drug · Genetic · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional Results available

Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma

NCT00301873
View directory record Official record
Conditions
Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
Interventions
IV Zometa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

NCT01339039
View directory record Official record
Conditions
High Grade Glioma: Glioblastoma (GBM), High Grade Glioma: Gliosarcoma, Anaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions
Plerixafor, Bevacizumab, Surgery
Drug · Procedure
Lead sponsor
Patrick Y. Wen, MD
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

NCT01977677
View directory record Official record
Conditions
Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Medulloblastoma, Adult Mixed Glioma, Adult Oligodendroglial Tumors, Adult Pineoblastoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Interventions
radiation therapy, temozolomide, plerixafor, laboratory biomarker analysis, pharmacological study
Radiation · Drug · Other
Lead sponsor
Lawrence Recht
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 1 Interventional

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

NCT03283631
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
EGFRvIII-CARs
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

NCT03020602
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma, Astrocytoma of Brain, Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Ubidecarenone Injectable Nanosuspension
Other · Drug
Lead sponsor
Seema Nagpal
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor

NCT00069940
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Gastrointestinal Stromal Tumor, Sarcoma
Interventions
sargramostim, telomerase: 540-548 peptide vaccine
Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 28, 2010 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer

NCT00014573
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, autologous tumor cell vaccine, filgrastim, sargramostim, therapeutic autologous lymphocytes, carmustine, cisplatin, cyclophosphamide, paclitaxel, autologous bone marrow transplantation, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

NCT00074243
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CC-8490
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

NCT01189240
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis, pharmacological study
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas

NCT00610571
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions
Oral Topotecan and Temodar
Drug
Lead sponsor
Katy Peters
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 1 Interventional

Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma

NCT00019071
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
chemotherapy, cladribine, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 11, 2026, 10:15 PM EDT
Terminated Phase 2 Interventional Results available

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

NCT01836549
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Astrocytoma, Grade II, Ependymoma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Oligodendroglioma, Brainstem Tumors
Interventions
imetelstat sodium
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
12 Months to 21 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 11, 2026, 10:15 PM EDT
Completed Phase 2 Interventional

Talampanel in Treating Patients With Recurrent High-Grade Glioma

NCT00064363
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
talampanel
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 11, 2026, 10:15 PM EDT